Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | TTR | P02766 | 8/20 | 0.44 |
| ▸ | RBP4 | P02753 | 7/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26712604 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HTR1ASSTR4 | |
| SCHEMBL25312528 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HTR1ASSTR4 | |
| SCHEMBL25186844 | 0.92 | CTSS (0.47) | SLC6A2SLC6A4SLC6A3SSTR4TTR | |
| SCHEMBL22265752 | 0.91 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HTR1ASSTR4 | |
| Hydrochloric Acid SCHEMBL1477666 | 0.90 | HTR2C (0.51) | SLC6A2SLC6A4SLC6A3HTR1ASSTR4 | |
| SCHEMBL2297017 | 0.88 | SSTR4 (0.52) | SLC6A2SLC6A4SLC6A3HTR1ASSTR4 | |
| SCHEMBL13034308 | 0.86 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3HTR1ARBP4 | |
| Hydrochloric Acid SCHEMBL3094594 | 0.84 | SLC6A2 (0.50) | SLC6A2SLC6A4SLC6A3HTR1ARBP4 | |
| SCHEMBL3895127 | 0.83 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3HTR1AHTR2C | |
| SCHEMBL30785484 | 0.82 | LTA4H (0.51) | SLC6A2SLC6A4SLC6A3HTR1ASSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023138592-A1 | SALT FORM CRYSTAL FORM OF PYRIMIDINE DERIVATIVE AND PREPARATION METHOD THEREFOR | 科岭源生物科技(深圳)有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-4181909-A2 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | The Trustees Of Columbia University In The City Of New York (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010100606-A1 | NOVEL PHENYL IMIDAZOLES AND PHENYL TRIAZOLES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | SLC6A2 4072/4885SLC6A4 3299/4885SLC6A3 3360/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | SLC6A2 1380/4885SLC6A4 809/4885SLC6A3 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.